Liposomal Irinotecan for Treatment of Colorectal Cancer in a Preclinical Model

Colorectal cancer (CRC) is the most frequently diagnosed cancer and leading cause of cancer-related deaths worldwide. Because of the use of first-line CRC treatments, such as irinotecan (IRI), is hindered by dose-limiting side effects, improved drug delivery systems may have major clinical benefits...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jiao-Ren, Lee, Mei-Hsien, Li, Wen-Shan, Wu, Han-Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468623/
https://www.ncbi.nlm.nih.gov/pubmed/30818855
http://dx.doi.org/10.3390/cancers11030281

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468623/
https://www.ncbi.nlm.nih.gov/pubmed/30818855
http://dx.doi.org/10.3390/cancers11030281

Ejemplares similares